Xianghong Wang

发表

Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H-benzimidazoles.

J. Treanor, C. Dominguez, C. Fotsch, 2006, Journal of medicinal chemistry.

Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.

K. Pattabiraman, Zhulun Wang, C. Quéva, 2014, Journal of medicinal chemistry.

Azole-based inhibitors of AKT/PKB for the treatment of cancer.

Daniel J. Freeman, Q. Zeng, Guomin Yao, 2010, Bioorganic & medicinal chemistry letters.

Small Molecule Therapeutics Preclinical Evaluation of AMG 925 , a FLT 3 / CDK 4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia

A. Kamb, Ji Ma, J. Medina, 2014 .

(4-Piperidinylphenyl)aminoethyl amides as a novel class of non-covalent cathepsin K inhibitors.

V. Viswanadhan, J. Cheetham, A. Tasker, 2004, Bioorganic & medicinal chemistry letters.

New air-stable catalysts for general and efficient suzuki-miyaura cross-coupling reactions of heteroaryl chlorides.

M. Martinelli, M. Faul, P. Reider, 2006, Organic letters.

Trisubstituted pyrimidines as transient receptor potential vanilloid 1 (TRPV1) antagonists with improved solubility.

J. Treanor, P. Chakrabarti, N. Gavva, 2007, Bioorganic & medicinal chemistry letters.

Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia

Alexander Kamb, John Eksterowicz, C. Quéva, 2014, Molecular Cancer Therapeutics.

Is a Dual FLT 3 / CDK 4 Inhibitor with the Potential to Overcome FLT 3 Inhibitor Resistance in Acute Myeloid Leukemia

A. Kamb, K. Dai, L. Liang, 2015 .

AMG 925 Is a Dual FLT3/CDK4 Inhibitor with the Potential to Overcome FLT3 Inhibitor Resistance in Acute Myeloid Leukemia

A. Kamb, K. Dai, L. Liang, 2014, Molecular Cancer Therapeutics.

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies.

Sean P. Brown, Nick A. Paras, L. Poppe, 2018, Cancer discovery.

Design and synthesis of peripherally restricted transient receptor potential vanilloid 1 (TRPV1) antagonists.

P. Chakrabarti, E. Doherty, A. Bannon, 2008, Journal of medicinal chemistry.

Triptolide inhibits viability and migration while promotes apoptosis in nephroblastoma cells by regulation of miR-193b-3p.

Xianghong Wang, H. Li, Shiying Hang, 2019, Experimental and molecular pathology.

Discovery of potent, orally available vanilloid receptor-1 antagonists. Structure-activity relationship of N-aryl cinnamides.

N. Chen, J. Treanor, P. Chakrabarti, 2005, Journal of medicinal chemistry.

Cytochrome P450-mediated epoxidation of 2-aminothiazole-based AKT inhibitors: identification of novel GSH adducts and reduction of metabolic activation through structural changes guided by in silico and in vitro screening.

Q. Zeng, G. E. Wohlhieter, Guomin Yao, 2010, Chemical research in toxicology.

Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.

K. Pattabiraman, Zhulun Wang, C. Quéva, 2014, Journal of medicinal chemistry.